



**Spire Healthcare**

## **Spire Healthcare Group plc** (09084066) Notice of 2026 Annual General Meeting

This document is important and requires your immediate attention. If you are in any doubt as to any aspect of the proposals referred to in this document or as to the action you should take, you should consult your stockbroker, bank manager, solicitor, accountant or other professional adviser or other independent adviser authorised under the Financial Services and Markets Act 2000 immediately. If you have sold or otherwise transferred all your shares in Spire Healthcare Group plc, please pass this document, together with the accompanying Form of Proxy, to the purchaser or transferee, or to the stockbroker, bank or other agent through whom you made the sale or transfer, for transmission to the purchaser or transferee.

The twelfth annual general meeting of Spire Healthcare Group plc will be held at 3 Dorset Rise, London EC4Y 8EN on Thursday, 14 May 2026 at 11.00am (UK time).

**30 March 2026**

Dear Shareholder, the twelfth annual general meeting (the 'AGM' or the 'Meeting') of Spire Healthcare Group plc (the 'Company') will be held at 3 Dorset Rise, London EC4Y 8EN on Thursday, 14 May 2026 at 11.00am (UK time).

The Company is looking forward to welcoming Shareholders to the AGM. Whilst it is fully expected that Shareholders will be able to attend the Meeting in person, should any changes to arrangements be required these will be reported through the Company's website at [investors.spirehealthcare.com](http://investors.spirehealthcare.com) or a regulatory information service.

If you are unable to attend I recommend you to appoint the Chairman of the Meeting as your proxy online at [www.shareview.co.uk](http://www.shareview.co.uk) and further instructions are provided on the reverse of the enclosed form. Alternatively, complete, sign and return the enclosed proxy card to our registrar, Equiniti Limited ('Equiniti'). Proxy forms must be received by Equiniti no later than 11.00am (UK time) on Tuesday, 12 May 2026. If you hold your shares through a corporate sponsored nominee ('CSN'), you will need to cast your vote no later than 11.00am (UK time) on Monday, 11 May 2026.

Full details of the business of the AGM and the resolutions that will be put to Shareholders ('Resolutions') are set out in the enclosed Notice of the Meeting. The majority of the Resolutions are those that are dealt with as a matter of course at each annual general meeting of the Company. All of the Company's Directors will stand for re-election at the AGM in line with best practice.

The biographies of all Directors standing for re-election can be found on pages 8 to 10 of the Notice of the Meeting.

I would strongly encourage Shareholders to submit any questions in advance of the meeting by e-mail to [companysecretary@spirehealthcare.com](mailto:companysecretary@spirehealthcare.com). A summary of questions and responses will be put on the Company's website ahead of the Meeting.

All Resolutions will be voted on a poll which ensures Shareholders' votes are counted according to the number of shares held. Following the conclusion of the Meeting the results of the poll will be announced via a regulatory information service and made available on the Company's website at [investors.spirehealthcare.com](http://investors.spirehealthcare.com).

If you would like to receive Shareholder documents electronically, please register through the online service provided by Equiniti at [www.shareview.co.uk](http://www.shareview.co.uk).

**Recommendation**

Your Directors believe all the proposals to be considered at the Meeting to be in the best interests of the Company and its Shareholders as a whole. They therefore unanimously recommend Shareholders to vote in favour of each of these Resolutions, as they intend to in respect of their own beneficial shareholdings.

Yours faithfully

**Sir Ian Cheshire**  
Chairman

# Notice of the 2026 Annual General Meeting

NOTICE IS HEREBY GIVEN that the twelfth annual general meeting ('AGM' or the 'Meeting') of Spire Healthcare Group plc (the 'Company') will be held at 3 Dorset Rise, London EC4Y 8EN on Thursday, 14 May 2026 at 11.00am (UK time) for the transaction of the following business:

To consider and, if thought fit, to pass resolutions 1 to 18 below as ordinary resolutions and resolutions 19 to 22 below will be proposed as special resolutions (each a 'Resolution' and together the 'Resolutions'):

## Ordinary Resolutions

1. THAT the Annual Report and the audited accounts of the Company for the year ended 31 December 2025 be received (see Explanatory Notes on page 8).
2. THAT the Directors' remuneration report (excluding the part summarising the Directors' remuneration policy, which is on page 105) set out on pages 103 and 104, and pages 106 to 113 in the Annual Report and Accounts for the year ended 31 December 2025 be received and approved (see Explanatory Notes on page 8).
3. THAT a final dividend of 1.5 pence per ordinary share for the year ended 31 December 2025 be declared, to be paid on 19 June 2026 to holders of ordinary shares in the capital of the Company on the register of members at close of business on 22 May 2026 (see Explanatory Notes on page 8).
4. THAT Ms Jill Anderson be re-elected a Director of the Company (see Explanatory Notes on page 8).
5. THAT Mr Justin Ash be re-elected a Director of the Company (see Explanatory Notes on page 8).
6. THAT Ms Paula Bobbett be re-elected a Director of the Company (see Explanatory Notes on page 8).
7. THAT Ms Natalie Ceeney be re-elected a Director of the Company (see Explanatory Notes on page 9).
8. THAT Sir Ian Cheshire be re-elected a Director of the Company (see Explanatory Notes on page 9).
9. THAT Ms Jenny Kay be re-elected a Director of the Company (see Explanatory Notes on page 9).
10. THAT Mr Harbant Samra be re-elected a Director of the Company (see Explanatory Notes on page 9).
11. THAT Professor Cliff Shearman be re-elected a Director of the Company (see Explanatory Notes on page 9).
12. THAT Sir David Sloman be re-elected a Director of the Company (see Explanatory Notes on page 9).
13. THAT Dr. Ronnie van der Merwe be re-elected a Director of the Company (see Explanatory Notes on page 10).
14. THAT Ms Debbie White be re-elected a Director of the Company (see Explanatory Notes on page 10).
15. THAT Ernst & Young LLP be reappointed as Auditor of the Company to hold office from the conclusion of the Meeting until the conclusion of the next annual general meeting of the Company at which accounts are laid (see Explanatory Notes on page 10).
16. THAT the Directors be authorised, subject to the passing of Resolution 15 above, to determine the Auditor's remuneration (see Explanatory Notes on page 10).

17. THAT the Company and those companies which are subsidiaries of the Company at any time during the period for which this Resolution has effect be authorised for the purposes of Part 14 of the Companies Act 2006 (the 'Companies Act') during the period from the date of the passing of this Resolution to the end of the next annual general meeting or 13 August 2027, whichever is the earlier:

- (i) to make political donations to political parties, and/or independent election candidates;
- (ii) to make political donations to political organisations other than political parties; and
- (iii) to incur political expenditure,

up to an aggregate amount of £100,000 for all of the companies to which this authority relates taken together, and the amounts authorised under paragraphs (i) to (iii) shall in each case also be limited to £100,000.

Words and expressions defined for the purposes of Part 14 of the Companies Act shall have the same meaning in this Resolution (see Explanatory Notes on page 10).

18. THAT the Directors be generally and unconditionally authorised pursuant to and in accordance with Section 551 of the Companies Act to exercise all the powers of the Company to allot shares and grant rights to subscribe for or convert any security into shares:

- (a) up to an aggregate nominal amount of £1,342,532; and
- (b) comprising equity securities (as defined in the Companies Act) up to an aggregate nominal amount of £2,685,063 (including within such limit the nominal amount of any allotments or grants made under (a) above) in connection with or pursuant to an offer:
  - (i) to holders of ordinary shares in proportion (as nearly as may be practicable) to their existing holdings; and
  - (ii) to people who are holders of other equity securities if this is required by the rights of those securities or, if the Directors consider it necessary, as permitted by the rights of those securities,

and so that the Directors may impose any limits or restrictions and make any arrangements which they consider necessary or appropriate to deal with treasury shares, fractional entitlements, record dates, legal, regulatory or practical problems in, or under the laws of, any territory or any other matter.

These authorisations shall expire (unless previously renewed, varied or revoked by the Company in a general meeting) at the end of the next annual general meeting or on 13 August 2027, whichever is the earlier, save that the Company may, at any time before such expiry, make any offer, agreement or other arrangement which would, or might, require shares to be allotted or rights to be granted after such expiry and the Board may allot shares, and grant rights to subscribe for or to convert any security into shares pursuant to any such offer, agreement or other arrangement as if the authorisations conferred hereby had not expired and provided that these authorisations shall (without prejudice to the continuing authority of the Directors to allot shares, or grant rights to subscribe for or convert any security into shares, pursuant to an offer or agreement made by the Company before the expiry of the authority pursuant to which such offer or agreement was made) be in substitution for and to the exclusion of all previous authorities conferred on the Directors to allot relevant securities.

## Special Resolutions

19. THAT, subject to the passing of Resolution 18 and in place of all existing powers, the Directors be generally empowered pursuant to Section 570 and Section 573 of the Companies Act to allot equity securities (as defined in the Companies Act) for cash, pursuant to the authority given by Resolution 18, as if Section 561(1) of the Companies Act did not apply to the allotment. This power:
- (a) expires (unless previously renewed, varied or revoked by the Company in general meeting) at the end of the next annual general meeting of the Company after the date on which this resolution is passed (or, if earlier, at the close of business on 13 August 2027), but the Company may make an offer or agreement which would or might require equity securities to be allotted after expiry of this power and the Directors may allot equity securities in pursuance of that offer or agreement as if this power had not expired; and
  - (b) shall be limited to:
    - (i) the allotment of equity securities in connection with an offer of equity securities:
      - (A) to the holders of ordinary shares in proportion (as nearly as may be practicable) to their existing holdings; and
      - (B) to people who are holders of other equity securities, if this is required by the rights of those securities or, if the Directors consider it necessary, as permitted by the rights of those securities,
- and so that the Directors may impose any limits or restrictions and make any arrangements which they consider necessary or appropriate to deal with treasury shares, fractional entitlements, record dates, legal, regulatory or practical problems in, or under the laws of, any territory or any other matter arising in connection with such offer; and
- (ii) in the case of the authority given under Resolution 18(a), the allotment of equity securities (otherwise than pursuant to paragraph (b)(i) and paragraph (b)(iii)) up to an aggregate nominal amount of £402,759; and
  - (iii) when any allotment of equity securities is or has been made pursuant to paragraph (b)(ii) (a 'paragraph (b)(ii) allotment'), the allotment of additional equity securities (also pursuant to the authority given under Resolution 18(a)) up to an aggregate nominal amount equal to 20% of the nominal amount of that paragraph (b)(ii) allotment, provided that any allotment pursuant to this paragraph (b)(iii) is for the purposes of a follow-on offer determined by the Directors to be of a kind contemplated by paragraph 3 of section 2B of the Statement of Principles on Disapplying Pre-Emption Rights most recently published by the Pre-Emption Group prior to the date of the notice of the meeting; and
- (c) applies in relation to a sale of shares which is an allotment of equity securities by virtue of Section 560(3) of the Companies Act as if in the first paragraph of this resolution the words 'pursuant to the authority given by Resolution 18' were omitted (see Explanatory Notes on pages 10 and 11).
20. THAT, subject to the passing of Resolution 18 and in addition to any power given to them pursuant to Resolution 19, the Directors be generally empowered pursuant to Section 570 and Section 573 of the Companies Act to allot equity securities (as defined in the Companies Act) for cash, pursuant to the authority given by Resolution 18, as if Section 561(1) of the Companies Act did not apply to the allotment. This power:
- (a) expires (unless previously renewed, varied or revoked by the Company in general meeting) at the end of the next annual general meeting of the Company after the date on which this resolution is passed (or, if earlier, at the close of business on 13 August 2027), but the Company may make an offer or agreement which would or might require equity securities to be allotted after expiry of this power and the Directors may allot equity securities in pursuance of that offer or agreement as if this power had not expired; and
  - (b) in the case of the authority given under Resolution 18(a), shall be limited to:
    - (i) the allotment of equity securities (otherwise than pursuant to paragraph (b)(ii)) up to an aggregate nominal amount of £402,759, provided that the allotment is for the purposes of financing (or refinancing, if the power is used within twelve months of the original transaction) a transaction which the Directors determine to be an acquisition or specified capital investment of a kind contemplated by the Statement of Principles on Disapplying Pre-emption Rights most recently published by the Pre-emption Group prior to the date of the Notice; and
    - (ii) when any allotment of equity securities is or has been made pursuant to paragraph (b)(i) ('a paragraph (b)(i) allotment'), the allotment of equity securities up to an aggregate nominal amount equal to 20% of the nominal amount of that paragraph (b)(i) allotment, provided that any allotment pursuant to this paragraph (b)(ii) is for the purposes of a follow-on offer determined by the Directors to be of a kind contemplated by paragraph 3 of section 2B of the Statement of Principles on Disapplying Pre-Emption Rights most recently published by the Pre-Emption Group prior to the date of the Notice; and
  - (c) applies in relation to a sale of shares which is an allotment of equity securities by virtue of Section 560(3) of the Companies Act as if in the first paragraph of this resolution the words 'pursuant to the authority given by Resolution 18' were omitted (see Explanatory Notes on pages 10 and 11).

21. THAT the Company be generally and unconditionally authorised for the purposes of Section 701 of the Companies Act to make market purchases (within the meaning of Section 693(4) of the Companies Act) of any of its ordinary shares in the capital of the Company on such terms and in such manner as the Directors may determine from time to time, provided that:
- (a) the maximum number of ordinary shares hereby authorised to be purchased is 40,275,960, representing 10 per cent. of the issued share capital of the Company as at 27 March 2026;
  - (b) the minimum price (exclusive of expenses) which may be paid for each ordinary share is £0.01, being the nominal value of an ordinary share;
  - (c) the maximum price (exclusive of expenses) which may be paid for each ordinary share is an amount equal to the higher of:
    - (i) 105 per cent. of the average of the middle market quotations for an ordinary share of the Company as derived from the Daily Official List of the London Stock Exchange for the five business days immediately preceding the day on which such ordinary share is contracted to be purchased; and
    - (ii) the higher of the price of the last independent trade of an ordinary share of the Company and the highest current independent bid for an ordinary share of the Company on the trading venue where the purchase is carried out;
  - (d) unless previously renewed, revoked or varied by the Company in a general meeting, this authority shall expire at the end of the next annual general meeting or on 13 August 2027, whichever is earlier; and
  - (e) the Company may, before the expiry of this authority, make a contract to purchase ordinary shares which would or might be executed wholly or partly after the expiry of this authority, and may make purchases of ordinary shares pursuant to it, as if this authority had not expired (see Explanatory Notes on page 11).
22. THAT a general meeting other than an annual general meeting may be called on not less than 14 clear days' notice (see Explanatory Notes on page 11).

By Order of the Board

**Sir Ian Cheshire**  
Chairman  
30 March 2026

Registered office: 3 Dorset Rise, London EC4Y 8EN

Registered in England and Wales No. 09084066

# Notes

1. Shareholders that are unable to attend the AGM are strongly encouraged to appoint the Chairman of the Meeting as their proxy to cast their vote as they so indicate.
2. Shareholders are entitled to appoint a proxy to exercise all or any of their rights to attend and to speak and vote on their behalf at the Meeting. A Shareholder may appoint more than one proxy in relation to the Meeting provided that each proxy is appointed to exercise the rights attached to a different share or shares held by that Shareholder. A proxy need not be a Shareholder of the Company. A proxy form which may be used to make such appointment and give proxy instructions accompanies this notice.
3. The appointment of a proxy must be in writing in any usual or common form or in any other form which the Directors may approve and (i) in the case of an individual must either be signed by the appointor or his attorney; and (ii) in the case of a corporation must either be given under its common seal or be signed on its behalf by an attorney or a duly authorised officer of the corporation. Any signature on, or authentication of, such appointment need not be witnessed. Where an appointment of a proxy is signed on behalf of the appointor by an attorney, the power of attorney or a copy thereof certified notarially or in some other way approved by the Directors must (failing previous registration with the Company) be submitted to the Company, failing which the appointment may be treated as invalid.
4. To be effective, the instrument appointing a proxy, and any power of attorney or other authority under which it is executed (or a duly certified copy of any such power or authority), must either be: (i) sent to the Company's Registrars, Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA; (ii) lodged using the CREST Proxy Voting Service (see Note 9 below); or (iii) for institutional investors you may be able to appoint a proxy electronically via [www.proxymity.io](http://www.proxymity.io), in each case so as to arrive no later than 11.00am (UK time) on Tuesday, 12 May 2026 or, if the AGM is adjourned, 48 hours before the time fixed for the adjourned AGM. Alternatively, Electronic Proxy Appointment ('EPA') is available for the AGM. To use this facility, you can register your proxy appointment and voting instructions by going to Equiniti's Shareview website, [www.shareview.co.uk](http://www.shareview.co.uk), and logging in to your Shareview Portfolio. To register for a Shareview Portfolio, go to [www.shareview.co.uk](http://www.shareview.co.uk) and enter the requested information. EPA will not be valid if received after 11.00am (UK time) on Tuesday, 12 May 2026 and will not be accepted if found to contain a computer virus.
5. The right to appoint a proxy does not apply to persons whose shares are held on their behalf by another person and who have been nominated to receive communications from the Company in accordance with Section 146 of the Companies Act ('Nominated persons'). Nominated persons may have a right under an agreement with the Shareholder on whose behalf they hold the shares to be appointed (or to have someone else appointed) as a proxy. Alternatively, if Nominated persons do not have such a right, or do not wish to exercise it, they may have a right under such an agreement to give instructions to the person holding the shares as to the exercise of voting rights.
6. Entitlement to vote at the AGM, and the number of votes which may be cast at the AGM, will be determined by reference to the Company's register of members at 6.30pm (UK time) on Tuesday, 12 May 2026 or, if the AGM is adjourned, at 6.30pm (UK time) on the day which is two days before the day fixed for the adjourned AGM (as the case may be). In each case, changes to the register of members after such time will be disregarded.
7. As at 27 March 2026 (which is the last practicable date before the publication of this Notice) the Company's issued share capital consisted of 402,759,599 shares, carrying one vote each on a poll. Therefore, the total voting rights in the Company as at 27 March 2026 were 402,759,599.
8. CREST Shareholders who wish to appoint a proxy through the CREST electronic proxy appointment service may do so for the AGM to be held on Thursday, 14 May 2026 and any adjournment(s) thereof by using the procedures described in the CREST Manual which can be viewed at [www.euroclear.com](http://www.euroclear.com). CREST personal Shareholders or other CREST sponsored Shareholders, and those CREST Shareholders who have appointed a voting service provider(s), should refer to their CREST sponsor or voting service provider(s), who will be able to take the appropriate action on their behalf.
9. In order for the appointment of a proxy or instruction made by means of CREST to be valid, the appropriate CREST message (a 'CREST Proxy Instruction') must be properly authenticated in accordance with Euroclear's specifications and must contain the information required for such instructions, as described in the CREST Manual. The message (regardless of whether it constitutes the appointment of a proxy, the revocation in appointment of a proxy or an amendment to the instruction given to a previously appointed proxy) must, in order to be valid, be transmitted so as to be received by the issuer's agent (ID RA19) by the latest time(s) for receipt of appointments of proxy specified in Note 4 above. For this purpose, the time of receipt will be taken to be the time (as determined by the timestamp applied to the message by the CREST Applications Host) from which the issuer's agent is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST. After this time any change of instructions to a proxy appointed through CREST should be communicated to the appointed Proxy by other means.
10. CREST Shareholders (and, where applicable, their CREST sponsors or voting service providers) should note that Euroclear does not make available special procedures in CREST for any particular messages. Normal system timings and limitations will therefore apply in relation to the input of CREST Proxy Instructions. It is the responsibility of the CREST Shareholder concerned to take (or, if the CREST Shareholder is a CREST personal Shareholder or sponsored Shareholder or has appointed a voting service provider, to procure that his CREST sponsor or voting service provider takes) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection, CREST Shareholders (and, where applicable, their CREST sponsors or voting service providers) are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings.
11. The Company may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001.
12. If you are an institutional investor you may be able to appoint a proxy electronically via the Proxymity platform, a process which has been agreed by the Company and approved by the Registrar. For further information regarding Proxymity, please go to [www.proxymity.io](http://www.proxymity.io). Your proxy must be lodged by 11.00am (UK time) on Tuesday, 12 May 2026 in order to be considered valid. Before you can appoint a proxy via this process you will need to have agreed to Proxymity's associated terms and conditions. It is important that you read these carefully as you will be bound by them and they will govern the electronic appointment of your proxy.
13. Any corporation which is a Shareholder can appoint one or more corporate representatives who may exercise on its behalf all of its powers, provided that if two or more representatives purport to vote in respect of the same shares: (i) if they purport to exercise the power in the same way as each other, the power is treated as exercised in that way; and (ii) in other cases, the power is treated as not exercised.

14. Shareholders should note that under Section 527 of the Companies Act it is possible that Shareholders meeting the threshold requirements set out in that section may require the Company to publish on a website a statement setting out any matter relating to: (i) the audit of the Company's accounts (including the Auditor's report and the conduct of the audit) that are to be laid before the AGM; or (ii) any circumstance connected with an Auditor of the Company appointed for the financial year ceasing to hold office since the previous meeting at which annual accounts and reports were laid. The Company may not require the Shareholder requesting any such website publication to pay its expenses in complying with Sections 527 or 528 (requirements as to website availability) of the Companies Act. Where the Company is required to place a statement on the website under Section 527 of the Companies Act, it must forward the statement to the Company's Auditor not later than the time when it makes the statement available on the website. The business which may be dealt with at the AGM for the relevant financial year includes any statement that the Company has been required under Section 527 of the Companies Act to publish on a website.
15. Shareholders are encouraged to submit any questions in advance by e-mail to [companysecretary@spirehealthcare.com](mailto:companysecretary@spirehealthcare.com). A summary of questions and responses will be put on the Company's website ahead of the Meeting. In accordance with Section 319A Companies Act, Shareholders (or their proxy) may, at the Meeting, ask questions relating to the business being dealt with at the Meeting. A question may not be answered at the Meeting if it is not considered to be in the interests of the Company or the good order of the Meeting, to do so would interfere unduly with the preparation for the Meeting or if it would involve the disclosure of sensitive information. The Chairman may also nominate a representative to answer a specific question after the Meeting or refer the questioner to the Company's website.
16. Shareholders have the right, under Section 338 of the Companies Act, to require the Company to give Shareholders entitled to receive notice of the AGM, notice of a resolution which the Shareholders wish to be moved at the Company's AGM. Additionally, Shareholders have the right under Section 338A of the Companies Act to require the Company to include a matter (other than a proposed Resolution) in the business to be dealt with at the AGM. The Company is required to give such notice of a resolution or include such matter once it has received requests from Shareholders representing at least 5% of the total voting rights of all the Shareholders who have a right to vote at the AGM or from at least 100 Shareholders with the same right to vote who hold shares in the Company on which there has been paid up an average sum per Shareholder of at least £100. A resolution may properly be moved or a matter may properly be included in the business unless:
- (i) (in the case of a resolution only) it would, if passed, be ineffective (whether by reason of inconsistency with any enactment or the Company's constitution or otherwise);
  - (ii) it is defamatory of any person; or
  - (iii) it is frivolous or vexatious.
- Such a request may be in hard copy form or electronic form, must identify the resolution of which notice is to be given or the matter to be included in the business, must be authorised by the person or persons making it, and must be received by the Company not later than six clear weeks before the AGM or, if later, the time at which notice is given of the AGM. In the case of a request relating to Section 338A of the Companies Act, the request must be accompanied by a statement setting out the grounds for the request.
17. In accordance with Section 311A of the Companies Act, the contents of this Notice of Meeting, details of the total number of shares in respect of which Shareholders are entitled to exercise voting rights at the AGM, details of the total number of the voting rights that Shareholders are entitled to exercise at the AGM and, if applicable, any Shareholders' statements, Shareholders' resolutions or Shareholders' matters of business received by the Company after the date of this Notice will be available on the Company's website at [investors.spirehealthcare.com](http://investors.spirehealthcare.com).
18. E-mail addresses provided in this Notice of Meeting or any related documents (including the Form of Proxy) should not be used to communicate with the Company for any purposes other than those expressly stated.
19. Each of the Resolutions to be put to the meeting will be voted on by poll. On a poll vote, every Shareholder proxy shall have one vote for every ordinary share of which he is the holder. This is a more transparent method of voting as Shareholders' votes are counted according to the number of shares held. As soon as practicable after the AGM the results of the poll (and other information required by Section 341 of the Companies Act) will be announced via a regulated information service and made available on the Company's website at [investors.spirehealthcare.com](http://investors.spirehealthcare.com).
20. Copies of all contracts of service or, where applicable, letters of appointment of the Directors are available for inspection during business hours at the registered office of the Company. So that appropriate arrangements can be made for Shareholders wanting to inspect documents, we request that Shareholders contact the Company Secretary at [companysecretary@spirehealthcare.com](mailto:companysecretary@spirehealthcare.com) in advance of any visit to ensure that access can be arranged. Any such access will be subject to health and safety requirements and any limits on gathering and social distancing and any other measures imposed or recommended by the UK Government.
21. The articles of association of the Company are available for inspection on the National Storage Mechanism and on the Company's website [investors.spirehealthcare.com](http://investors.spirehealthcare.com) and will be available for inspection at the AGM for at least 15 minutes prior to the meeting and during the meeting until its conclusion.
22. Only Shareholders of shares (or their proxy) are entitled to vote at the AGM. Only the first Shareholder listed on the Register of Members is entitled to vote.
23. This document is important and requires your immediate attention. If you are in any doubt as to any aspect of the proposals referred to in this document or as to the action you should take, you should consult your stockbroker, bank manager, solicitor, accountant or other professional adviser or other independent adviser authorised under the Financial Services and Markets Act 2000 immediately. If you have sold or otherwise transferred all your shares in Spire Healthcare Group plc, please pass this document, together with the accompanying Form of Proxy, to the purchaser or transferee, or to the stockbroker, bank or other agent through whom you made the sale or transfer, for transmission to the purchaser or transferee.

# Explanatory Notes to Business of the 2026 Annual General Meeting

## Ordinary and Special Resolutions

Resolutions 19 to 22 are special resolutions; the remainder are ordinary resolutions. Ordinary resolutions require a simple majority of Shareholders voting in person or by proxy to pass the resolutions, whereas special resolutions require at least 75% of Shareholders voting in person or by proxy to pass the resolutions.

## Items of business

### Receipt of 2025 Annual Report (Resolution 1)

Resolution 1 deals with the receipt of the 2025 Annual Report and audited accounts of the Company for the financial year ended 31 December 2025. The Directors must present the annual accounts, the strategic report, the directors' report and the auditors' report to Shareholders at the AGM.

### Remuneration Report (Resolution 2)

In accordance with the provisions of the Companies Act the Directors' Remuneration Report contained within the 2025 Annual Report comprises:

- an Annual Statement from the Remuneration Committee chair, Natalie Ceeney; and
- the Annual Report on Remuneration.

Resolution 2 seeks Shareholder approval for the Directors' Remuneration Report as set out on pages 103 and 104, and pages 106 to 113 of the 2025 Annual Report. This vote by ordinary resolution is advisory in nature, meaning that payments and benefits made or promised to Directors would not have to be repaid or withheld should the resolution not be passed. The Company's Auditor, Ernst & Young LLP, has audited those parts of the report that are required to be audited and its report can be found on pages 118 to 125 of the 2025 Annual Report.

### Final Dividend (Resolution 3)

Resolution 3 deals with the declaration of the final dividend of 1.5 pence per ordinary share for the year ended 31 December 2025. A final dividend can only be paid after the Shareholders at a general meeting have approved it. If approved, the final dividend will be paid on 19 June 2026 to Shareholders on the register of members at close of business on 22 May 2026.

### Re-election of Directors (Resolutions 4 to 14)

All the Directors will retire and offer themselves for re-election at the AGM in accordance with the Company's Articles of Association and the UK Corporate Governance Code (which recommends that all Directors of FTSE 350 companies be subject to annual re-election by Shareholders). The re-elections of Directors will take effect at the conclusion of the Meeting.

The Board has considered whether each of the non-executive directors is free from any relationship that could materially interfere with the exercise of their independent judgement. It has concluded that, with the exception of Dr Ronnie van der Merwe who has been appointed to the Board by the Company's principal Shareholder and Sir David Sloman, who has, and has had in the last three years, a material business relationship with the Company as a result of his appointment as a non-executive director of AXA UK and Ireland, each Director is independent.

The Company completed a formal review of the Board's performance and effectiveness in 2025 in relation to the fulfilment of its duty to act in the long-term interest of the Company on behalf of its Shareholders (while also having due regard for other stakeholders). This was facilitated by BoardClic. The 2025 Board performance review concluded that the Board was operating effectively, in an open and transparent manner, and providing support and challenge to senior management. Each Non-Executive Director has shown sufficient time commitment to the role. As such, the Chairman recommends the re-election of each of the Directors standing.

The biographies on pages 8 to 10 contain details of the individual skills and experience that each Director brings to the Board and why they contribute to the long-term sustainable success of the Company. Further information on skills and experience can be found on page 93 of the 2025 Annual Report.

## Jill Anderson, Independent Non-Executive Director



Jill Anderson was appointed an independent non-executive director in March 2025.

### Current external appointments

- Non-executive director of Croda International plc
- Trustee of Amref UK, an NGO focused on healthcare in Africa

### Skills and previous experience

Jill is an experienced CFO. Her last full-time executive role was as chief financial officer for research and development at GSK which was preceded by a number of senior roles at GSK including chief financial officer for ViiV Healthcare. Jill has over 30 years' experience in the pharmaceutical sector in finance, commercial, research and supply chain functions.

Jill started her career at Shell plc on the finance graduate programme and is an accountant. She has a chemistry degree from Exeter University.

## Justin Ash, Chief Executive Officer



Justin Ash was appointed chief executive officer and an executive director in October 2017.

### Current external appointments

- Member of the strategic council of Independent Healthcare Providers Network
- Chair of the trustees of Global Health Partnerships
- Fellow of the Institute of Directors

### Skills and previous experience

Justin was previously chief executive of Oasis Dental Care between 2008 and 2017 before leading its sale to Bupa, managing director of Lloyds Pharmacy and held senior positions at KFC and Allied Domecq. He is a member of the Strategic Council for the Independent Healthcare Providers Network and is chair of trustees for Global Health Partnerships. He is a trustee of Fraxinus Trust and chair of the Freemasons Fund for Surgical Research.

## Paula Bobbett, Independent Non-Executive Director



Paula Bobbett was appointed an independent non-executive director in November 2022.

### Current external appointments

- Chief data and digital officer of Boots UK

### Skills and previous experience

Paula is a senior executive with extensive experience across four key pillars of modern retail: commercial, digital, strategy, and data. Currently serving as Chief Data and Digital Officer at Boots, Paula leads omnichannel digital customer experience and drives large-scale digital transformation initiatives in retail and healthcare. Her career is marked by a proven ability to influence at board level, implement change, and deliver material business growth.

Prior to joining Boots UK, Paula was interim E-Comm director at Dixons Carphone. She has held senior analytics and customer insight roles at a variety of companies, including Avon and Debenhams, as well as roles at British Airways and Vanguard Strategy.

## Key to committees

- Audit and risk committee
- Clinical governance and safety committee
- Nomination committee
- Remuneration committee
- Committee chair

## Natalie Ceeny CBE, Independent Non-Executive Director



Natalie Ceeny was appointed an independent non-executive director in May 2023.

### Current external appointments

- Chair of Cash Access UK Limited
- Non-executive director of Openreach Limited
- Chair of the Connection Project Limited

### Skills and previous experience

Natalie spent more than 20 years leading organisational and digital transformation, firstly as a McKinsey & Company consultant and then as an executive. She has worked across a range of sectors, both public and private, and has experience as a regulator as well as a CEO. Natalie has a focus on and deep interest in meeting the needs of customers, inclusion, and the transformational nature of technology.

Natalie's executive career included chief executive roles at HM Courts & Tribunals Service, the Financial Ombudsman Service, the National Archives and as a member of HSBC's UK executive team. Her non-executive career has included roles on the boards of Anglian Water Services Ltd, Ford Credit Europe Ltd, Liverpool Victoria (LV) and Innovate Finance. Natalie is a graduate of the University of Cambridge.

## Sir Ian Cheshire, Chairman



Sir Ian Cheshire joined Spire Healthcare as chairman-designate in early March 2021 and became non-executive chairman at the conclusion of its annual general meeting in May 2021.

### Current external appointments

- Chairman of Land Securities Group plc
- Senior adviser to Ardea Partners
- Chair of the Institute for Government
- Chair of We Mean Business Coalition
- Chair of trustees for King Charles III Charitable Fund

### Skills and previous experience

Sir Ian brings to Spire Healthcare considerable FTSE experience, deep understanding of the government-business interface and broad ESG credentials, which are important to the Company's strategy and long-term sustainable success.

Sir Ian was chairman of Barclays Bank UK PLC until December 2020 and a non-executive director of Barclays PLC, BT Group plc and Menhaden Resource Efficiency plc until May 2021, July 2023 and September 2024 respectively. He was also previously senior independent director and remuneration committee chair of Whitbread plc until September 2017. Sir Ian held a variety of posts whilst at Kingfisher plc including chief executive of B&Q from 2005 to 2008 and group chief executive from 2008 to 2014. He is involved with many charitable organisations, such as King Charles III Charitable Fund, and has also worked with various government departments.

## Jenny Kay, Independent Non-Executive Director



Jenny Kay was appointed an independent non-executive director in June 2019. She has been designated Spire Healthcare's non-executive director lead for safeguarding and the board's Freedom to Speak Up Guardian

### Skills and previous experience

Jenny has extensive experience as a front-line registered nurse and subsequent experience in senior management and board roles across the NHS including as director of nursing at Dartford and Gravesham NHS Trust in Kent. She was a senior independent director at East London NHS Foundation Trust until the end of December 2020. Jenny also worked at the Department of Health in the chief nursing officer's team, leading on communications. Additionally, Jenny has experience as director of quality in a clinical commissioning group.

Jenny's clinical background is in children's nursing – she was a ward sister at King's College Hospital for many years, specialising in care for children with liver disease and children requiring intensive care. Jenny trained at St Thomas' (RGN) and Guy's Hospitals (RSCN).

Before commencing her nursing career, Jenny studied languages at Durham University and she also has an MBA from the Bristol Business School.

## Harbant Samra, Chief Financial Officer

Harbant Samra was appointed chief financial officer and an executive director in May 2024.

### Skills and previous experience

Harbant joined Spire Healthcare in October 2018 as group financial controller after a successful 20-year career in financial services. He was appointed interim chief financial officer in January 2022 while Spire's former chief financial officer was away from the business recovering from an accident, and then deputy chief financial officer in October 2022.

Harbant started his career at Deloitte in 1996 as part of its graduate scheme and qualified as a chartered accountant (ICAEW) in 1999. He was promoted to director in Deloitte's Financial Services department in 2006 before leaving to join Lloyds Banking Group in 2011 as head of group financial reporting. While at Lloyds Banking Group, Harbant was promoted to finance director, group financial reporting in 2013 and during this time led on large scale transformation programmes and on its response to UK regulatory structural reform matters.

## Professor Cliff Shearman, Independent Non-Executive Director



Professor Cliff Shearman was appointed an independent non-executive director in October 2020.

### Current external appointments

- Emeritus professor of vascular surgery, University of Southampton

### Skills and previous experience

Cliff was non-executive director of the Royal Bournemouth and Christchurch NHS Foundation Trust from 2017 to 2020 and subsequently University Hospitals Dorset NHS Foundation Trust from 2020 to 2025. He chaired the Quality Committee and was vice chair of the Trust.

Cliff was a consultant vascular surgeon for 26 years, initially in Birmingham and then in Southampton, and professor of vascular surgery at the University of Southampton. His research interests focus on factors that lead to diabetic vascular disease and how to improve clinical outcomes for people with diabetes. He campaigned for improved services at a local, regional and national level.

Cliff was a clinical service director and associate medical director in the University Hospital Southampton. At a national level he was president of the Vascular Society of Great Britain and Ireland and was one of the team that separated vascular surgery from general surgery leading to a new speciality, centralisation of services and a new training programme for vascular surgeons. These changes have been associated with dramatic improvements in outcomes for patients. Cliff was a member of the council and a trustee of the Royal College of Surgeons of England, serving as vice president from 2018 until July 2021. He was awarded an OBE in 2021 for services to vascular surgery.

## Sir David Sloman, Vice Chair



Sir David Sloman was appointed a non-executive director in March 2025 and vice chair in May 2025. The company does not consider Sir David Sloman to be independent as a result of his appointment with AXA UK and Ireland.

### Current external appointments

- Non-executive director of AXA UK and Ireland
- Board member of Health Data Research UK
- Board member of Accurx
- Visiting professor in the Institute of Global Health Innovation, Imperial College London
- Fellow of the Royal Society of Medicine
- Senior fellow of the Institute for Healthcare Improvement

### Skills and previous experience

Sir David has had a long career in healthcare management, predominantly in the NHS. He has held several CEO roles at several NHS trusts, including the Royal Free London NHS Foundation Trust, the Whittington Hospital NHS Trust and NHS Haringey Trust. During December 2021 and August 2023, he was the COO of NHS England, where he was responsible for overseeing all NHS operational delivery, including the response to the COVID-19 pandemic.

# Explanatory Notes to Business of the 2026 Annual General Meeting continued

## Dr Ronnie van der Merwe, Non-Executive Director

(N)

Dr Ronnie van der Merwe was appointed as a non-executive director in May 2018. The company does not consider Ronnie to be independent as he has been appointed to the board by the Company's principal Shareholder, Mediclinic Group Limited, under the terms of the relationship agreement with them.

### Current external appointments

– Group chief executive officer of the Mediclinic group of companies (Mediclinic)

### Skills and previous experience

Ronnie has a strong track record of leadership and management within the healthcare industry, including strategy, organisational development, clinical performance, adoption of technology, and quality and data management.

As a specialist anaesthesiologist in private practice, Ronnie gained extensive experience in trauma and elective anaesthesia, intensive care management, and the management of acute and chronic pain. He subsequently expanded his expertise at medical insurance company Sanlam Health before joining Mediclinic in 1999. As chief clinical officer, he took responsibility for various aspects of the business, contributed greatly to the growth and strategic positioning of the group, and served as chair of the board of trustees of the in-house medical aid scheme, Remedi. He also served on the board of the premier private emergency medical care provider in South Africa, ER24, and as executive director of Mediclinic from 2010. He was appointed as group chief executive officer of Mediclinic in 2018.

## Debbie White, Senior Independent Director

(A) (N)

Debbie White was appointed an independent non-executive director in February 2023 and became senior independent director in May 2023.

### Current external appointments

- Non-executive director and chair of The Co-operative Group
- Director of PAVmed Inc (listed on the NASDAQ)
- Director of Lucid Diagnostics Inc (listed on the NASDAQ)
- Director of Xanitos
- Director of APCOA
- Trustee and honorary treasurer for the charity Wellbeing of Women
- Trustee of the charity Place 2 Be

### Skills and previous experience

Debbie is an experienced CEO and independent director. Her last full-time executive role was as chief executive officer of Interserve Group, which was preceded by a number of senior executive roles at Sodexo SA including global chief executive officer of Sodexo Healthcare and Sodexo Government, chief financial officer of the North American and UK&I businesses and chief executive officer of Sodexo UK&I. She was interim group HR director for BT Group plc during 2022, supporting the executive on the transformation of the group. Debbie was a non-executive director of Howden Joinery Group plc until December 2023.

Debbie started her career with Arthur Andersen and is a chartered accountant and chartered tax practitioner. She joined AstraZeneca where she held a variety of financial roles, before joining Sodexo. Debbie was a director of PWC consulting where she advised principally in the pharmaceutical sector.

## Reappointment of Auditor and authorisation of Directors to determine its remuneration (Resolutions 15 and 16)

The auditors of a company must be reappointed at each general meeting at which accounts are laid. Resolutions 15 and 16 deal, respectively, with the reappointment of Ernst & Young LLP as Auditor of the Company (following the recommendation of the Audit and Risk Committee) and the authorisation of the Directors to determine its remuneration for the current financial year. The level of remuneration paid in 2025 by way of audit fees to the Auditor, together with the amounts paid in respect of non-audit fees, are shown in Note 7 on page 139 of the 2025 Annual Report and Accounts.

## Authority for the Company to incur political expenditure (Resolution 17)

Resolution 17 is an ordinary resolution which authorises the Company and its UK subsidiaries to make political donations and to incur political expenditure. The Companies Act requires companies to obtain Shareholders' authority for donations to registered political parties, other political organisations and independent election candidates totalling more than £5,000 in any 12-month period, and for any political expenditure, subject to limited exceptions. The definitions of 'donations', 'political organisations', 'independent election candidates' and 'political expenditure' are very wide in this context and there is concern that they may have had the effect of covering a number of normal business activities that would not be thought to be political donations in the usual sense.

As required by the Companies Act, the Resolution is in general terms and does not purport to authorise particular donations. It remains the policy of the Company not to make political donations or incur political expenditure as those expressions are normally understood, and the Company has no present intention of using such authority granted. A similar resolution was approved by Shareholders at the last annual general meeting on 14 May 2025.

Hence, to avoid inadvertent infringement of the Companies Act, the Directors are again seeking Shareholders' authority for the Company and its subsidiaries to make political donations and to incur political expenditure during the period from the passing of the Resolution until the conclusion of the Company's next annual general meeting or 13 August 2027, whichever is the earlier, up to a maximum aggregate amount of £100,000.

## Directors' authority to allot shares (Resolution 18)

Under section 551 of the Companies Act the Directors may only allot shares and grant rights to subscribe for, or convert any security into, shares (unless pursuant to an employees' share scheme) if authorised to do so by the Shareholders in a general meeting. The authority conferred on the Directors at last year's annual general meeting held on 14 May 2025 under Section 551 of the Companies Act to allot shares expires on the date of the AGM. Resolution 18 gives the Directors a new section 551 authority starting from the date of the AGM.

Resolution 18 seeks new authority to allow the Directors to allot shares and grant rights to subscribe for or convert any security into shares: (a) up to an aggregate nominal amount of £1,342,532; and (b) in connection with a pre-emptive offer to Shareholders (with exclusions to deal with fractional entitlements to shares and overseas Shareholders to whom the offer cannot be made due to legal and practical problems) up to an aggregate nominal amount (reduced by allotments under part (a) of the Resolution) of £2,685,063.

These amounts represent no more than one-third and two-thirds respectively of the Company's total issued share capital as at 27 March 2026 (being the latest practicable date prior to publication of this document). The authorities granted in Resolution 18 will expire on the date of the Company's next annual general meeting or 13 August 2027, whichever is the earlier.

The Investment Association guidance on the Directors' authority to allot permits resolutions seeking authority to allot shares representing two-thirds of the Company's issued share capital, provided that the extra authority (i.e. that provided by part (b) of Resolution 18) shall only be used to allot shares pursuant to a fully pre-emptive offer.

The Company has no present intention of exercising this authority other than in connection with any outstanding share option awards. However, if they do exercise the authority, the Directors intend to follow emerging best practice as regards its use as recommended by the Investment Association. The Company's Directors intend to renew this authority annually.

The Directors consider it desirable to have the maximum flexibility permitted by corporate governance guidelines to respond to market developments and to enable allotments to take place.

The Company holds no treasury shares as at 27 March 2026 (being the latest practicable date prior to publication of this document).

## Special Resolutions

### Disapplication of pre-emption rights (Resolutions 19 and 20)

If the Directors wish to allot shares, or grant rights to subscribe for, or convert securities into, shares, or sell treasury shares, for cash (unless pursuant to an employees' share scheme), they must first offer them to existing Shareholders in proportion to their holdings. There may be occasions when the Directors need the flexibility to finance business opportunities by allotting shares without a pre-emptive offer to existing Shareholders, and this can be done if the Shareholders have first given a limited waiver of their pre-emption rights. Resolution 19 and Resolution 20 ask Shareholders to grant this limited waiver. The Resolutions will be proposed as special resolutions.

Resolution 19 contains a three-part waiver. The first part is limited to the allotment of shares for cash on a pre-emptive basis to allow the Directors to make appropriate exclusions and other arrangements to resolve legal or practical problems which, for example, might arise in relation to overseas Shareholders. The second part is limited to the allotment of shares for cash up to an aggregate nominal value of £402,759 (which includes the sale on a non-pre-emptive basis of any shares held in treasury), which represents approximately 10% of the Company's issued share capital as at 27 March 2026 (the latest practicable date before the publication of this notice). The third part applies to the allotment of shares for cash for the purposes of a follow-on offer when an allotment of shares has been made under the second waiver. It is limited to the allotment of shares having an aggregate nominal value of up to 20% of the nominal value of any shares allotted under the second waiver. The follow-on offer must be determined by the Directors to be of a kind contemplated by the Pre-Emption Group's 2022 Statement of Principles. The Directors confirm that they will follow the shareholder protections in section 2B and the expected features of a follow-on offer in paragraph 3 of section 2B of the Pre-Emption Group's 2022 Statement of Principles.

The waiver granted by Resolution 20 is in addition to the waiver granted by Resolution 19 and itself has two parts. The first part is limited to the allotment of shares for cash up to an aggregate nominal value of £402,759 (which includes the sale on a non-pre-emptive basis of any shares held in treasury), which represents a further 10% (approximately) of the Company's issued share capital as at 27 March 2026 (the latest practicable date before the publication of this notice). The first part of the waiver may only be used for an allotment of shares for cash for the purposes of financing (or refinancing, if the waiver is used within twelve months of the original transaction) a transaction which the Directors determine to be an acquisition or specified capital investment of a kind contemplated by the Pre-emption Group's 2022 Statement of Principles. The second part of the waiver applies to the allotment of shares for cash for the purposes of a follow-on offer when an allotment of shares has been made under the first part of the waiver. It is limited to the allotment of shares having an aggregate nominal value of up to 20% of the nominal value of any shares allotted under the first waiver. The follow-on offer must be determined by the Directors to be of a kind contemplated by the Pre-Emption Group's 2022 Statement of Principles. The Directors confirm that they will follow the shareholder protections in section 2B and the expected features of a follow-on offer in paragraph 3 of section 2B of the Pre-Emption Group's 2022 Statement of Principles.

If the Resolutions are passed, the waivers will expire at the conclusion of the next annual general meeting or, if earlier, the close of business on 13 August 2027.

### Authority for the Company to purchase its own shares (Resolution 21)

Resolution 21 to be proposed at the annual general meeting will, if passed, renew the Company's authority granted at last year's annual general meeting which expires on the date of the forthcoming AGM. The authority would permit the Company to purchase up to 40,275,960 ordinary shares (which represents 10 per cent. of the Company's issued ordinary share capital as at 27 March 2026, being the latest practicable date prior to the publication of this document). The maximum and minimum prices are stated in the Resolution. This authority would provide the Company with additional flexibility in the management of its capital base.

The Directors have no present intention of exercising this authority and, in the event that market purchases were made, the shares would be cancelled and the number of shares in issue reduced accordingly or, in accordance with the Companies Act, retained as treasury shares. The authority will be exercised only if the Directors believe that to do so would result in an increase in earnings per share and would be likely to promote the success of the Company for the benefit of its Shareholders as a whole. Any purchases of ordinary shares would be by means of market purchases through the London Stock Exchange. Treasury shares may subsequently be cancelled, sold for cash or used to satisfy options issued to employees pursuant to the employees' share schemes. This authority is in line with the UK Listing Rules of the Financial Conduct Authority and the Investment Association's guidance.

As at 27 March 2026 there were options over 10,515,947 ordinary shares in the capital of the Company which represent 2.62% of the issued ordinary share capital (excluding treasury shares) at that date. If the authority to purchase ordinary shares was exercised in full, these options would represent 2.91% of the issued ordinary share capital (excluding treasury shares).

This authority shall expire at the end of the next annual general meeting or on 13 August 2027, whichever is earlier.

### Authority for the Company to call a general meeting on 14 clear days' notice (Resolution 22)

Under the Companies Act, the notice period required for all general meetings of the Company is 21 days. Annual general meetings will always be held on at least 21 clear days' notice but Shareholders can approve a shorter notice period for other general meetings, as long as this is not less than 14 clear days.


Resolution 22 is a special resolution which will preserve the ability of the Company to call general meetings (other than an annual general meeting) on 14 clear days' notice. The Company does not propose to use this reduced notice period as a matter of routine, but wishes to maintain the flexibility to do so where it is merited by the business of the meeting (for example because the matter to be discussed is time sensitive) and is thought to be to the advantage of Shareholders as a whole. The approval will be effective until the Company's next annual general meeting, when it is intended that a similar resolution will be proposed.

The Company will also need to meet the requirements for electronic voting under the Companies (Shareholders' Rights) Regulations 2009 in order to be able to call a general meeting on 14 clear days' notice.

# Attending the 2026 Annual General Meeting

If you are planning to attend the AGM it will be held at the Company's head office at 3 Dorset Rise, London EC4Y 8EN. This is a short walk from Blackfriars station, which can be accessed from both the District and Circle London Underground lines and also main line services. Nearby Blackfriars Bridge, Fleet Street, Victoria Embankment and New Bridge Street are all well served by London buses.

The venue has facilities for attendees with disabilities and, if you require assistance, please contact the Company Secretary prior to the Meeting by e-mail at [companysecretary@spirehealthcare.com](mailto:companysecretary@spirehealthcare.com). There will be an opportunity to meet the Company's Directors both before and after the Meeting.



## Glossary

### Definitions

'2025 Annual Report'	The annual report and accounts of the Company for the year ended 31 December 2025
'AGM' or the 'Meeting'	The 2026 annual general meeting, notice of which is contained in this document
'Board'	The board of directors of the Company
'Companies Act'	The Companies Act 2006
'Company'	Spire Healthcare Group plc, registered in England and Wales with company number 09084066
'Director'	A director of the Company
'Notice'	This notice of the AGM
'Resolution'	The resolutions set out in this Notice to be considered at the AGM
'Share'	An ordinary share of 1 pence each in the capital of the Company
'Shareholder'	A holder of shares
'UK Listing Rules'	The listing rules produced by the Financial Conduct Authority under Part VI of the Financial Services and Markets Act 2000, as amended

### Spire Healthcare Group plc

3 Dorset Rise, London  
EC4Y 8EN

Company number: 09084066  
Registered in England and Wales

[spirehealthcare.com](http://spirehealthcare.com)